Head to Head Analysis: Abivax (ABVX) & Its Competitors

Abivax (NASDAQ:ABVX) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare Abivax to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares Abivax and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	N/A	N/A
Abivax Competitors	-1,425.99%	-589.65%	-28.81%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abivax and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1	0	9	2	3.00
Abivax Competitors	5740	12157	37592	1156	2.60

Abivax currently has a consensus price target of $121.11, suggesting a potential downside of 1.46%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 58.77%. Given Abivax’s peers higher possible upside, analysts clearly believe Abivax has less favorable growth aspects than its peers.

Institutional and Insider Ownership

47.9% of Abivax shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.6% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Abivax has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Abivax’s peers have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Abivax and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Abivax	N/A	-$190.71 million	-71.04
Abivax Competitors	$950.94 million	-$45.25 million	11.68

Abivax’s peers have higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Abivax peers beat Abivax on 7 of the 13 factors compared.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.